research Treatment of moderate-to-severe alopecia areata in adolescents with baricitinib: A retrospective review of 29 patients
Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.
Search
for
Sort by
Research
270-300 / 1000+ results 
research New plaque protein identified in brains of people with Alzheimer's disease
Scientists found a new protein, AMY117, common in Alzheimer's patients, which could be important for treatment and diagnosis.
research Improvement in health‐related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international randomized controlled trials
Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
research Therapeutic Burden as Predictor of Response to Baricitinib for Alopecia Areata in Real Life: Prospective Study
Patients with fewer past treatments for alopecia areata respond better to baricitinib.
research Single Best Answers
The document provides 70 multiple choice questions to improve haematology skills.
research Eyebrows and Eyelashes Regrowth Across Different SALT Response Thresholds in Patients with Alopecia Areata: Outcomes from the BRAVE AA Clinical Program
research Dermatoscopic of pseudocyst of the scalp
Both azathioprine and betamethasone treatments help with hair regrowth in alopecia areata, but azathioprine may have fewer side effects.
research 1406 DETECTION OF MEMBRANE ANDROGEN-BINDING SITE IN LIVING RAT PROSTATE AND EVALUATION OF ITS ROLE IN PROSTATE BLOOD FLOW REGULATION
The research found that androgens help control blood flow in the rat prostate through a specific binding site.
research Alefacept for Severe Alopecia Areata
Alefacept does not effectively treat severe alopecia areata.
research Beard hair response in Alopecia Areata Universalis treated with baricitinib
Baricitinib effectively promotes beard regrowth in most men with alopecia areata universalis.
research This Month in JAAD: October 2021
Oral baricitinib is effective and safe for treating alopecia areata.
research A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol
Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.
research Budget impact analysis of baricitinib for treatment of alopecia areata: A Saudi hospital perspective
Adding baricitinib will increase costs but offers more treatment options for alopecia areata.
research Assessment of Intestinal Free Fatty Acid Binding Protein 4 in Alopecia Areata Patients
Higher FABP4 levels may indicate more severe alopecia areata.
research Single-Administration Long-Acting Microarray Patch with Ultrahigh Loading Capacity and Multiple Releases of Thermally Stable Antibodies
A new patch can deliver stable antibodies over time for potential HIV treatment.
research 5ARI and PSA: open questions
5ARI treatment improves PSA test accuracy for prostate cancer diagnosis.
research SALT Score Cards: Facilitating SALT Score Calculation in Alopecia Areata
A new tool simplifies alopecia areata severity scoring but needs validation.
research An anti‐hair loss treatment in the management of mild androgenetic alopecia: results from a large, international observational study
AC5 improves hair loss and hair quality with high satisfaction rates.
![Discovery of (2S)-N-(6-Cyano-5-(Trifluoromethyl)Pyridin-3-Yl)-3-(6-(4-Cyanophenyl)-3,6-Diazabicyclo[3.1.1]Heptan-3-Yl)-2-Hydroxy-2-Methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment](/images/research/693e7bf6-2325-4ddc-a20f-3470db9f4516/small/25627.jpg)
research Discovery of (2S)-N-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-2-hydroxy-2-methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment
A new topical treatment for hair loss shows strong hair growth effects with low toxicity.
research ABHRS NEWS
The ABHRS is expanding globally and advancing hair restoration surgery.
research Squaric Acid Dibutylester Promotes Innate Immune-Driven Hair Growth with CD206+ Macrophage Accumulation in the Dermis
Squaric acid dibutylester promotes hair growth by activating immune cells, especially macrophages.
research Identification of BST2 as a biomarker for alopecia areata in both mice and humans
BST2 is a key marker for hair loss disease alopecia areata.
research Faculty Opinions recommendation of Androgenetic alopecia as an early marker of benign prostatic hyperplasia.
Hair loss can be an early sign of prostate enlargement.
research Most Baricitinib Responders Achieved Full Scalp Hair Regrowth: Findings from Adult and Paediatric BRAVE-AA Trials
Baricitinib effectively regrows scalp hair in most people with severe alopecia areata.
research Arachis hypogaea L. Root Extract Mitigates Testosterone Propionate‐Induced Benign Prostatic Hyperplasia in ICR Mice by Suppressing Inflammation, Androgen Receptors, and Dihydrotestosterone
Arachis hypogaea L. root extract reduces prostate enlargement and inflammation in mice.
research CS12192 Reverses Alopecia Areata by Selectively Targeting JAK3/JAK1/TBK1.
CS12192 effectively treats alopecia areata with better safety than current options.
research The effects of finasteride (FIN) and thioacetamide (TAA) on acetylcholinesterase (AchE) activity in various brain regions.
research AI03 Steps towards safely deploying the world’s first autonomous artificial intelligence as a medical device for skin cancer into a National Health Service teledermatology pathway
An AI device for skin cancer was successfully integrated into the NHS, improving diagnosis accuracy and service capacity.
research BASP-Classification of Androgenetic Alopecia: Application Experience in Men
The M-type is the most common form of male hair loss, and the BASP-classification is easy for different medical professionals to use.
research Evaluation of serum Level of Human Beta Defensin 1 patients With Alopecia Areata
Human Beta Defensin 1 levels do not predict the risk or severity of Alopecia Areata.